热搜词：
注册
登录
CN
  • CN
  • EN

产品中心 药物靶点和Fc受体 药物靶点

所有图片（1/1）

LY75/CD205 His Tag Protein, Human

LY75,CD205,DEC-205,CLEC13B,Lymphocyte antigen 75,gp200-MR6

价格 ￥1,280.00 （ 供应商现货 ： 3-5个工作日）
货号 UA011116
规格
数量
收藏 分享
产品介绍

产品介绍 评论(0)

产品规格

  • 物种

    Human

  • 分子别名

    LY75, CD205, DEC-205, CLEC13B, Lymphocyte antigen 75, gp200-MR6

  • Accession

    O60449-1

  • 表达序列

    Ser28-Asp1666 with His Tag at C-Terminus

  • 表达宿主

    HEK293

  • 分子量

    170-200kDa (Reducing)

  • 纯度

    ＞95% by SDS-PAGE

  • 标记

    Unconjugated

  • 标签

    His Tag

  • 性状

    Lyophilized Powder

  • 缓冲体系

    PBS, PH7.4, 5% trehalose

  • 溶解方法

    Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.

  • 储存条件

    · 12 months from date of receipt, lyophilized powder stored at -20 to -80℃.
    · 3 months, -20 to -80℃ under sterile conditions after reconstitution.
    · 1 week, 2 to 8℃ under sterile conditions after reconstitution.
    · Please avoid repeated freeze-thaw cycles.

  • 文献引用

    Yun Z, Liu Z, Shen Y, Sun Z, Zhao H, Du X, Lv L, Zhang Y, Hou L. Genetic analysis from multiple cohorts implies causality between 2200 druggable genes, telomere length, and leukemia. Comput Biol Med. 2024 Oct;181:109064.

背景介绍

  • Lymphocyte antigen 75 (Ly75), also known as CD205, CLEC13B, GP200-MR6, and DEC-205, is a type I transmembrane protein predominantly expressed on dendritic cells and thymic epithelial cells. Ly75 functions as an endocytic receptor for antigens. MEN1309/OBT076, the first antibody drug targeting CD205, has demonstrated strong preclinical anti-tumor activity in lymphoma models.
    Upon verification as a monotherapy in vivo, the antibody-drug conjugate (ADC) has been found to have a synergistic effect when combined with the BCL2 inhibitor Venetoclax and the anti-CD20 monoclonal antibody rituximab.

  • 电泳

    • 1μg (R: reducing condition, N: non-reducing condition).

评论(0)